Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting

J Hematol Oncol. 2024 Apr 16;17(1):18. doi: 10.1186/s13045-024-01539-4.

Abstract

The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; several prospective studies involving these drugs have demonstrated high remission rates and promising, albeit short, survival outcomes. This review summarizes the latest updates on chemo-free regimens in the treatment of adult patients with Ph + ALL, presented at the 2023 ASH annual meeting.

Keywords: Blinatumomab; Chemo-free; Ph + ALL; TKIs; Venetoclax.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Congresses as Topic
  • Humans
  • Philadelphia Chromosome
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Prospective Studies
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors